CorMedix Inc.
NGM: CRMDLive Quote
About CorMedix Inc.
Healthcare
Biotechnology
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
📊 Fundamental Analysis
CorMedix Inc. demonstrates exceptional profitability, with a profit margin of 52.3%.
The company recently reported 312.1% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is 66.6%, which reflects exceptional capital efficiency.
At a current price of $7.24, CRMD currently trades near the bottom of its 52-week range (10%), indicating potential value or weakness (Range: $6.13 - $17.43).
💰 Valuation Insight
CRMD trades at a 85.8% discount (PE: 3.55), which may represent a value opportunity given the sector average of 25.00. Analysts anticipate some earnings pressure, with a higher forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
✅
Return on Equity
Excellent
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$678.61M
Trailing P/E
3.55
Forward P/E
9.92
Beta (5Y)
1.41
52W High
$17.43
52W Low
$6.13
Avg Volume
1.78M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App